Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer
Completed · Phase 2
Conditions studied: Non-Small Cell Lung Cancer
In brief
A study to evaluate the safety of Nivolumab in participants with advanced or metastatic non-small cell lung cancer
Key facts
- Study ID
- NCT03090737
- Run by
- Bristol-Myers Squibb
- People needed
- 129
- Starts
- 2017-06-02
- Expected to finish
- 2022-03-14
- Last updated by the study team
- 2022-12-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Non small cell lung cancer (Squamous or non-squamous)
- At least one prior anti-cancer therapy that did not work
- ECOG Performance Scale 0-1
You may not qualify if…
- Cancer that has spread to the brain or leptomeninges unless there is no evidence of progression by MRI for 8 weeks after treatment is complete and within 28 days before first dose of study drug
- Active, known or suspected autoimmune disease or infection
- Prior immuno-oncology therapy
- Corticosteroids within 2 weeks of study drug administration
- Other protocol defined inclusion/exclusion criteria could apply
Where it is running
- Alabama Oncology — Birmingham, Alabama, United States
- Los Angeles Hematology Oncology Medical Group — Los Angeles, California, United States
- St Vincent Frontier Cancer Center — Billings, Montana, United States
- Broome Oncology — Johnson City, New York, United States
- Guthrie Medical Group Sayre — Sayre, Pennsylvania, United States
- Local Institution - 0015 — Kingston, Ontario, Canada
- Local Institution - 0014 — Oshawa, Ontario, Canada
- Local Institution - 0001 — Toronto, Ontario, Canada
- Local Institution - 0017 — Nagoya, Aichi-ken, Japan
- Local Institution - 0023 — Osaka, Osaka, Japan
- Local Institution - 0018 — Koto-ku, Tokyo, Japan
- Local Institution - 0016 — Tokyo, Japan
- Local Institution - 0003 — Craiova, Romania
- Local Institution - 0006 — Sector 2, Romania
- Local Institution - 0011 — Port Elizabeth, Eastern Cape, South Africa
- Local Institution - 0013 — Parktown, Johannesburg, Gauteng, South Africa
- Local Institution - 0012 — George, Western Cape, South Africa
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.